Minerva Neurosciences NERV
NASDAQ NERV
$4.43 -0.26 (-5.54%)
At close: Sep 4, 2026 · 4:00 PM EDT

Minerva Neurosciences (NERV) Retained Earnings (2013 - 2026)

Minerva Neurosciences' (NERV) quarterly Retained Earnings came in at -$814.2 million in Q1 2026, down 103.99% YoY from $20.4 billion in Q1 2025, and down 18.21% on a QoQ basis from -$688.8 million in Q4 2025.

Analysis

Minerva Neurosciences (NERV) Retained Earnings (2013 - 2026) Analysis & Trends

Minerva Neurosciences (NERV) has 14 years of Retained Earnings data on file, last reported at -$814.2 million in Q1 2026.

  • Quarterly Retained Earnings fell 103.99% year-over-year to -$814.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$814.2 million (down 103.99% YoY) and the FY2025 annual result came in at -$688.8 million, down 74.21% from the prior year.
  • Retained Earnings slipped to -$814.2 million in Q1 2026, from -$688.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$344.5 million in Q1 2022 to a low of -$814.2 million in Q1 2026.
  • A 5-year average of -$428.1 million and a median of -$395.4 million in 2024 frame the typical range for Retained Earnings.
  • Annual changes were most pronounced in 2025 — Retained Earnings grew 2.71% — and 2026, when it slumped 103.99%.
  • Tracing NERV's Retained Earnings over 5 years: stood at -$366.8 million in 2022, then fell by 8.18% to -$396.8 million in 2023, then increased by 0.36% to -$395.4 million in 2024, then plunged by 74.21% to -$688.8 million in 2025, then dropped by 18.21% to -$814.2 million in 2026.
  • The last three Retained Earnings figures came in at -$814.2 million (Q1 2026), -$688.8 million (Q4 2025), and -$405.1 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 15.69 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 37.62 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 558.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 5.10 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -4.00 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 13.05 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -6.33 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 4.38 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 6.57 Bn
10 Minerva Neurosciences 207.37 Mn 207.37 Mn - -796.74 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -796.74 Mn
Mar 31, 2026 -814.20 Mn
Dec 31, 2025 -688.80 Mn
Sep 30, 2025 -405.13 Mn
Jun 30, 2025 -402.40 Mn
Mar 31, 2025 -399.13 Mn
Dec 31, 2024 -395.38 Mn
Sep 30, 2024 -391.10 Mn
Jun 30, 2024 -413.62 Mn
Mar 31, 2024 -405.40 Mn
Dec 31, 2023 -396.82 Mn
Sep 30, 2023 -387.80 Mn
Jun 30, 2023 -380.00 Mn
Mar 31, 2023 -373.80 Mn
Dec 31, 2022 -366.81 Mn
Sep 30, 2022 -360.10 Mn
Jun 30, 2022 -353.20 Mn
Mar 31, 2022 -344.47 Mn
Dec 31, 2021 -334.70 Mn
Sep 30, 2021 -313.40 Mn